Payment overview · 2025
General Payments
$513.33
24 reported records · 16 companies
Healthcare provider profile · identity verified
Daryl R Burrows, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · HOT SPRINGS, AR · NPI 1619191863
Verified facts
What the public records show
CMS Open Payments records show Daryl R Burrows, MD received $513.33 in general payments during 2025 across 24 reported records.
Radius Health, Inc. accounted for 13.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Prolia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 279 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $66.94 | 13.0% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $55.78 | 10.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.27 | 10.6% | 3 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $53.34 | 10.4% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $47.39 | 9.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.09 | 9.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.15 | 5.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.82 | 4.5% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.15 | 4.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.84 | 3.7% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $18.83 | 3.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.42 | 3.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.26 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.10 | 3.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.02 | 3.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $13.93 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $513.33 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $66.94 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $55.78 | 2 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $53.34 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $53.34 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $53.34 | 2 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $47.39 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 279 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
110 | 30 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
39 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
279 | 51 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1595 | 275 |
| Methimazole | Methimazole | 578 | 109 |
| Ozempic | Semaglutide | 279 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 68 |
| Metformin Hcl Er | Metformin Hcl | 193 | 41 |
| Alendronate Sodium | Alendronate Sodium | 177 | 43 |
| Ezetimibe | Ezetimibe | 170 | 33 |
| Atorvastatin Calcium | Atorvastatin Calcium | 159 | 46 |
| Metformin Hcl | Metformin Hcl | 154 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 136 | 40 |
| Glimepiride | Glimepiride | 126 | 34 |
| Novolog Flexpen | Insulin Aspart | 121 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 120 | 35 |
| Synthroid | Levothyroxine Sodium | 110 | 30 |
| Testosterone Cypionate | Testosterone Cypionate | 110 | 28 |
| Januvia | Sitagliptin Phosphate | 107 | 23 |
| Mounjaro | Tirzepatide | 106 | 16 |
| Hydrocortisone | Hydrocortisone | 105 | 18 |
| Gabapentin | Gabapentin | 93 | 19 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 82 | 23 |
| Jardiance | Empagliflozin | 73 | 14 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 66 | 14 |
| Lisinopril | Lisinopril | 63 | 12 |
| Novolog | Insulin Aspart | 63 | 13 |
| Calcitriol | Calcitriol | 61 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 61 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 55 | 15 |
| Armour Thyroid | Thyroid,pork | 52 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 52 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Repatha Sureclick | Evolocumab | 49 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 47 | suppressed |
| Fenofibrate | Fenofibrate | 46 | suppressed |
| Losartan Potassium | Losartan Potassium | 44 | 12 |
| Amlodipine Besylate | Amlodipine Besylate | 42 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 41 | suppressed |
| Propylthiouracil | Propylthiouracil | 41 | suppressed |
| Prolia | Denosumab | 39 | 29 |
| Insulin Lispro | Insulin Lispro | 38 | suppressed |
| Humalog | Insulin Lispro | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 33 | suppressed |
| Furosemide | Furosemide | 32 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | 12 |
| Praluent Pen | Alirocumab | 30 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $513.33 · 24 records | Radius Health, Inc. | Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, ISTURISA, Kerendia, LEQVIO, MINIMED 780G, Ozempic, Rybelsus, STRENSIQ, TEPEZZA, TWIIST, TZIELD, Tymlos, XYOSTED, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error